Maraviroc for previously treated patients with R5 HIV-1 infection.

ABSTRACT:

Background

CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.

Methods

We conducted two double-blind, placebo-controlled, phase 3 studies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2--with patients who had R5 human immunodeficiency virus type 1 (HIV-1) only. They had been treated with or had resistance to three antiretroviral-drug classes and had HIV-1 RNA levels of more than 5000 copies per milliliter. The patients were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy (OBT) based on treatment history and drug-resistance testing. Safety and effi

SUBMITTER: Gulick RM 

PROVIDER: S-EPMC3078519 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature